Pancreatic Cancer Research

ResearcherYokohama City UniversityActive in the last 2 years

Hiroshi Tamagawa

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112176226. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 11

  1. Clinical Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgical Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16805↗
  2. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. Co-author DOI 10.1186/s12957-023-03141-3↗
  3. Postoperative acute pancreatitis after pancreatic resection in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-022-02481-0↗
  4. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-insti… Co-author DOI 10.21873/invivo.11780↗
  5. The Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Pancreatic Cancer. Co-author DOI 10.21873/invivo.11931↗
  6. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuva… Co-author DOI 10.4103/jcrt.jcrt_440_18↗
  7. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. Co-author DOI 10.7150/jca.28660↗
  8. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.12801↗
  9. The clinical significance of SWI/SNF complex in pancreatic cancer. Co-author DOI 10.3892/ijo.2012.1723↗
  10. The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with su… Co-author DOI 10.1016/j.ejso.2012.08.008↗
  11. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adju… Co-author DOI 10.1245/s10434-011-2054-z↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Soichiro Morinaga · 11 shared papers, 2012–2024 · strength 0.98
  2. Naoto Yamamoto · 10 shared papers, 2012–2024 · strength 0.95
  3. Masaaki Murakawa · 8 shared papers, 2018–2024 · strength 0.89
  4. Makoto Ueno · 7 shared papers, 2018–2024 · strength 0.79
  5. Satoshi Kobayashi · 6 shared papers, 2018–2024 · strength 0.66
  6. Manabu Morimoto · 6 shared papers, 2018–2023 · strength 0.63
  7. Toru Aoyama · 6 shared papers, 2018–2024 · strength 0.60
  8. Yuto Kamioka · 4 shared papers, 2020–2024 · strength 0.55
  9. Mariko Kamiya · 5 shared papers, 2018–2024 · strength 0.51
  10. Shinnosuke Kawahara · 3 shared papers, 2022–2024 · strength 0.46
  11. Masakatsu Numata · 6 shared papers, 2012–2020 · strength 0.40
  12. Takashi Oshima · 3 shared papers, 2018–2024 · strength 0.32
  13. Yohei Miyagi · 4 shared papers, 2012–2019 · strength 0.17
  14. Makoto Akaike · 3 shared papers, 2012–2013 · strength 0.09
  15. Shinichi Ohkawa · 2 shared papers, 2012 · strength 0.06
  16. T. Watanabe · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.